Results 41 to 50 of about 71,029 (345)

Intravitreal Bevacizumab and Triamcinolone for Treatment of Cystoid Macular Oedema Associated with Chronic Myeloid Leukaemia and Imatinib Therapy

Case Reports in Ophthalmological Medicine, 2015
Purpose. To evaluate the efficacy of intravitreal bevacizumab and triamcinolone in the treatment of cystoid macular oedema in a case with chronic myeloid leukaemia on imatinib treatment. Methods.
Eric K. Newcott, Abdallah A. Ellabban, Shokufeh Tavassoli, Ahmed Sallam   +3 more
doaj   +1 more source

Slovenian recommendations for the management of chronic myeloid leukaemia

Zdravniški Vestnik, 2018
The paper presents recommendations for the management of patients with chronic myeloid leukaemia. Clinical manifestations, diagnostics, treatment and monitoring of treatment are presented.
Irena Preložnik Zupan, Karla Rener, Helena Podgornik, Matjaž Sever, Martina Fink, Mateja Grat, Tadej Pajič   +6 more
doaj   +1 more source

Apoptotic effect of Bulbine Natalensis and Chlorophytum Comosum in myelogenous Leukemia K562 cell line

Brazilian Journal of Biology, 2021
Bulbine natalensis and Chorophytum comosum are potential medicinal source for the treatment of cancers. Chronic myeloid leukaemia is a hematopoietic stem cells disorder treated by tyrosine kinase inhibitors but often cause recurrence of the leukaemia ...
B. Padayachee, F. Odun-Ayo, L. Reddy
doaj   +1 more source

Analogue peptides for the immunotherapy of human acute myeloid leukemia [PDF]

, 2015
Accepted manuscript. The final publication is available at: http://link.springer.com/article/10.1007%2Fs00262-015-1762-9The use of peptide vaccines, enhanced by adjuvants, has shown some efficacy in clinical trials.
A Driessche Van, A Gros, A Scardino, A Serrano, A Sevko, A Snyder, A Tsuboi, AB Bakker, Aleksandrs Malinovskis, Andrew Mead, AT Cheuk, AW Purcell, B Engels, B Falini, B Maecker, B Maecker, B Uttenthal, BA Guinn, BA Guinn, Barbara-ann Guinn, C Chaise, C Maccalli, CL Slingluff Jr, D Cilloni, D Mason, DA Gross, DE Speiser, DH Chang, DJ Schwartzentruber, E Estey, E Romano, F Ghiringhelli, FS Hodi, G Khan, H Kobayashi, H Ohminami, HJ Kolb, HJ Stauss, I Bellantuono, J Bae, J Bae, J Fourcade, J Greiner, J Greiner, J Kronke, J Pinilla-Ibarz, J Pinilla-Ibarz, JH Sampson, JJ Molldrem, JL Chen, JL Chen, JN Kochenderfer, JS Ko, JW Wells, K Inoue, K Inoue, K Rezvani, K Rezvani, KM Zirlik, L Chan, L Fong, L Gao, LV Ly, M Harndahl, M Kapp, M Subklewe, MA Cheever, MG Warnock, MM Gubin, MR Parkhurst, MS Bijker, N Hardwick, Nicola R. Hardwick, O Christensen, O Hamid, P Brossart, P Bruggen van der, P Keskinen, PG Maslak, PG Maslak, R Cibotti, RA Padua, RF Schlenk, RJ May, S Frankild, S Hofmann, S Narayan, S Ochsenreither, S Pascolo, S Suekane, S Walter, SH Burg van der, SK Singh, SL Topalian, SP Adams, Susanne Hofmann, T Lovgren, U Keilholz, U Sahin, V Bhardwaj, WS Meng, Y Oka, Z Trajanoski   +102 more
core   +2 more sources

Study of the Relationship between Heme Oxygenase-1, Interleukins (6, 12) and Coenzyme Q10 in Iraqi Pediatric Patients with Chronic Myeloid Leukemia

Proceedings of the International Conference on Applied Innovations in IT
A global disorder impacted by both genetic and environmental factors, chronic myeloid leukaemia (CML) is associated with increasing mortality and morbidity rates and has social and economic consequences.
Mustafa Yassin Khalf, Wasan Nazhan Hussein   +1 more
doaj   +1 more source

Systemic mastocytosis with associated myeloproliferative disease and precursor B lymphoblastic leukaemia with t(13;13)(q12;q22) involving FLT3. [PDF]

, 2008
Systemic mastocytoses represent neoplastic proliferations of mast cells. In about 20% of cases systemic mastocytoses are accompanied by clonal haematopoietic non-mast cell-lineage disorders, most commonly myeloid neoplasms.
Dirnhofer, S., Horny, H.-P., Jotterand, M., Muhlematter, D., Sotlar, Karl, Theocharides, A., Tzankov, A., Went, P.   +7 more
core   +1 more source

Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors [PDF]

, 2002
FLT3 mutations, either internal tandem duplications (ITDs) or aspartate residue 835 (D835) point mutations, are present in approximately one third of patients with acute myeloid leukemia (AML) and have been associated with an increased relapse rate.
Bowen, D.T., Frew, M.E., Gale, R.E., Kottaridis, P.D., Langabeer, S.E., Linch, D.C.   +5 more
core   +1 more source

A Dasatinib-Induced Chylothorax Persisting After the Discontinuation of Dasatinib

European Journal of Case Reports in Internal Medicine, 2022
Dasatanib is a second-generation tyrosine kinase inhibitor with activity on the BCR-ABL fusion gene. it is used in the treatment of BCR-ABL positive chronic myeloid leukaemia and has the known side effect of pleural effusion.
Nicolas Bradt, Frederic Olbrechts, Patrick Alexander, Alexander Salembier   +3 more
doaj   +1 more source

Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment [PDF]

, 2009
Background: t(9;22) is a balanced translocation, and the chromosome 22 breakpoints (Philadelphia chromosome – Ph+) determine formation of different fusion genes that are associated with either Ph+ acute lymphatic leukemia (Ph+ ALL) or chronic myeloid ...
Henschler, Reinhard, Moore, Malcolm A. S., Oancea, Claudia, Ruthardt, Martin, Zheng, Xiaomin   +4 more
core   +3 more sources

Biological aspects of mTOR in leukemia [PDF]

, 2018
The mammalian target of rapamycin (mTOR) is a central processor of intra-and extracellular signals, regulating many fundamental cellular processes such as metabolism, growth, proliferation, and survival.
Bianchi, Mp, Gianfelici, V, Mirabilii, S, Piedimonte, M, Ricciardi, Mr, Tafuri, A.   +5 more
core   +1 more source